Back to results
US 2024/0197927 A1Published application
Combination comprising a neurotensin receptor binding compound, gemcitabine and nab-paclitaxel
AssigneeFusion Pharmaceuticals Inc.
InventorsDiane-Charlotte Imbs, Elodie Lewkowicz, Alexander McEwan, Thomas Rohban, Sylvie Rolland, Daniel Stevens, John R. Forbes
Life of this patent
Estimating the term…
Abstract
The present invention relates to a combination comprising a neurotensin receptor binding compound, gemcitabine and nab-paclitaxel for use for the treatment of a neurotensin receptor overexpressing tumour in a subject.
Claims17
A method of treating a neurotensin receptor overexpressing tumor, comprising administering to a subject in need thereof a therapeutically effective amount of a combination comprising a neurotensin receptor binding compound, gemcitabine and nab-paclitaxel.
Dependencies are inferred from the claim text.